Cassava Sciences, Inc. (SAVA)
Fuera de horario:
Cassava Sciences, Inc.
6801 N. Capital of Texas Highway
Suite 300 Building 1
Austin, TX 78731
United States
512 501 2444
https://www.cassavasciences.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 29
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Remi Barbier | Founder, Chairman, President & CEO | 1.2M | 598.57k | 1960 |
| Mr. Eric J. Schoen | Chief Financial Officer | 460k | N/D | 1968 |
| Mr. R. Christopher Cook | Senior VP, Company Secretary & General Counsel | 425k | N/D | 1964 |
| Dr. James W. Kupiec M.D. | Chief Medical Officer | 435k | N/D | 1953 |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology | N/D | N/D | N/D |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations | N/D | N/D | N/D |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
| Dr. Lindsay H. Burns Ph.D. | Senior Vice President of Neuroscience | N/D | N/D | N/D |
Descripción
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Cassava Sciences, Inc. a partir del 1 de abril de 2024 es 9. Las puntuaciones principales son Auditoría: 10; Junta: 10; Derechos del accionista: 8; Compensación: 8.
